Midazolam, a water-soluble benzodiazepine, for gastroscopy

Area of Science:

• Pharmacology
• Gastroenterology
• Clinical Medicine

Background:

• Sedation is crucial for endoscopic procedures like oesophago-gastro-duodenoscopy.
• Traditional sedatives such as diazepam can cause adverse effects like injection pain and venous thrombosis.
• Midazolam, a water-soluble benzodiazepine, presents a potential alternative for procedural sedation.

Purpose of the Study:

• To evaluate the efficacy and safety of intravenous midazolam for sedation during oesophago-gastro-duodenoscopy.
• To compare the sedative effects of midazolam in different age groups (elderly vs. young patients).
• To assess the incidence of adverse events associated with midazolam compared to diazepam.

Main Methods:

• A study involving 40 patients undergoing oesophago-gastro-duodenoscopy.
• Intravenous administration of midazolam at a dose of 0.07 mg/kg for sedation.
• Observation and recording of sedative effectiveness and adverse events.

Main Results:

• Midazolam demonstrated high sedative effectiveness in elderly patients.
• Sedative efficacy was lower in younger patients, with significant individual response variations.
• No instances of pain on injection or venous thrombosis were observed with midazolam.
• Adverse effects commonly seen with diazepam were notably absent.

Conclusions:

• Intravenous midazolam is an effective and safe sedative for elderly patients undergoing oesophago-gastro-duodenoscopy.
• Midazolam offers an improved safety profile over diazepam, reducing the risk of injection site complications.
• Further research may be needed to optimize midazolam dosage for younger patient populations.